Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6200)
All Articles published online
|
Publishing Process of This Article
|
Feb 21, 2015 (publication date) through May 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang JS, Jing CQ, Shan KS, Chen YZ, Guo XB, Cao ZX, Mu LJ, Peng LP, Zhou ML, Li LP. Semaphorin 4D and hypoxia-inducible factor-1α overexpression is related to prognosis in colorectal carcinoma. World J Gastroenterol 2015; 21(7): 2191-2198 [PMID: 25717256 DOI: 10.3748/wjg.v21.i7.2191] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i7/2191.htm |
| Number | Citing Articles |
| 1 |
Mahsa Rezaeepoor, Golnaz Rashidi, Mona Pourjafar, Chiman Mohammadi, Ghasem Solgi, Rezvan Najafi, Somchai Chutipongtanate. SEMA4D Knockdown Attenuates β-Catenin-Dependent Tumor Progression in Colorectal Cancer. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/8507373
|
| 2 |
Patricia Carrasco, Iratxe Zuazo-Gaztelu, Oriol Casanovas. Sprouting strategies and dead ends in anti-angiogenic targeting of NETs. Journal of Molecular Endocrinology 2017; 59(1): R77 doi: 10.1530/JME-17-0029
|
| 3 |
Kimia T. Maleki, Martin Cornillet, Niklas K. Björkström. Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases. Clinical Immunology 2016; 163: 52 doi: 10.1016/j.clim.2015.12.012
|
| 4 |
Adewale Oluwaseun Fadaka, Taiwo Akinsoji, Ashwil Klein, Abram Madimabe Madiehe, Mervin Meyer, Marshall Keyster, Lucky Mashudu Sikhwivhilu, Nicole Remaliah Samantha Sibuyi. Stage-specific treatment of colorectal cancer: A microRNA-nanocomposite approach. Journal of Pharmaceutical Analysis 2023; 13(11): 1235 doi: 10.1016/j.jpha.2023.07.008
|
| 5 |
Amita Patnaik, Glen J. Weiss, John E. Leonard, Drew Warren Rasco, Jasgit C. Sachdev, Terrence L. Fisher, Laurie A. Winter, Christine Reilly, Robert B. Parker, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, Maurice Zauderer, Ramesh K. Ramanathan. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clinical Cancer Research 2016; 22(4): 827 doi: 10.1158/1078-0432.CCR-15-0431
|
| 6 |
Aijun Yu, Luwen Zhao, Qingmin Kang, Kai Chen, Jian Li, Hua Fu, Jinlong Liu, Xuejun Zhang. LncRNA LINC01061 sponges miR-612 to regulate the oncogenic role of SEMA4D in cholangiocarcinoma. Biochemical and Biophysical Research Communications 2019; 513(2): 465 doi: 10.1016/j.bbrc.2019.03.125
|
| 7 |
Anna Laber, Elisabeth Gadermaier, Jacqueline Wallwitz, Gabriela Berg, Gottfried Himmler. A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma. Analytical Biochemistry 2019; 574: 15 doi: 10.1016/j.ab.2019.03.004
|
| 8 |
Alexander J. Rossi, Tahsin M. Khan, Hanna Hong, Gregory B. Lesinski, Christina Wu, Jonathan M. Hernandez. Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer. Annals of Surgical Oncology 2021; 28(8): 4098 doi: 10.1245/s10434-021-10111-0
|
| 9 |
Satoshi Nojima. Class IV semaphorins in disease pathogenesis. Pathology International 2022; 72(10): 471 doi: 10.1111/pin.13270
|
| 10 |
Golnaz Rashidi, Mahsa Rezaeepoor, Chiman Mohammadi, Ghasem Solgi, Rezvan Najafi.
Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells. Molecular Biology Reports 2020; 47(9): 7017 doi: 10.1007/s11033-020-05761-4
|
| 11 |
Ying-Hua Yang, Asma Buhamrah, Abraham Schneider, Yi-Ling Lin, Hua Zhou, Amr Bugshan, John R. Basile, Chi Zhang. Semaphorin 4D Promotes Skeletal Metastasis in Breast Cancer. PLOS ONE 2016; 11(2): e0150151 doi: 10.1371/journal.pone.0150151
|
| 12 |
Keqian Zhang, Tianqi Mao, Zhicheng He, Xiaojiao Wu, Yu Peng, Yanrong Chen, Yan Dong, Zhihua Ruan, Zhe Wang. WITHDRAWN: Diagnostic performance of MASP-2 in the diagnosis of colorectal carcinoma. Pathology - Research and Practice 2020; : 153278 doi: 10.1016/j.prp.2020.153278
|
| 13 |
Elisabetta Valentini, Marta Di Martile, Donatella Del Bufalo, Simona D’Aguanno. SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia. Journal of Experimental & Clinical Cancer Research 2021; 40(1) doi: 10.1186/s13046-021-01929-3
|
| 14 |
Cecilia Bica, Alexandru Tirpe, Andreea Nutu, Cristina Ciocan, Sergiu Chira, Eugen S. Gurzau, Cornelia Braicu, Ioana Berindan-Neagoe. Emerging roles and mechanisms of semaphorins activity in cancer. Life Sciences 2023; 318: 121499 doi: 10.1016/j.lfs.2023.121499
|
| 15 |
Ji Peng, Shi Shen, Ju Wang, Hong Jiang, Yong Wang. Ηypoxia-inducible factor 1-α promotes colon cell proliferation and migration by upregulating AMPK-related protein kinase 5 under hypoxic conditions. Oncology Letters 2018; doi: 10.3892/ol.2018.7748
|
| 16 |
Shujie Zeng, Zihao Zhang, Chunshui Ye, Jinshen Wang, Changqing Jing, Leping Li. Mediating immunosuppressive functions: a new perspective on the complex immunological properties of SEMA4D in the tumor microenvironment. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1171926
|
| 17 |
Yan Wang, Hongli Zhao, Weiwei Zhi. SEMA4D under the posttranscriptional regulation of HuR and miR-4319 boosts cancer progression in esophageal squamous cell carcinoma. Cancer Biology & Therapy 2020; 21(2): 122 doi: 10.1080/15384047.2019.1669996
|
| 18 |
Yichen Liu, Xiaoqi Zhu, Xiaoyi Zhou, Jingwen Cheng, Xiaoyu Fu, Jingsheng Xu, Yuya Wang, Yueping Zhong, Minjie Chu. Different polymorphisms in HIF-1α may exhibit different effects on cancer risk in Asians: evidence from nearly forty thousand participants. Aging 2020; 12(21): 21329 doi: 10.18632/aging.103871
|
| 19 |
Tetsuro Ikeya, Kiyoshi Maeda, Hisashi Nagahara, Masatsune Shibutani, Yasuhito Iseki, Kosei Hirakawa. The combined expression of Semaphorin4D and PlexinB1 predicts disease recurrence in colorectal cancer. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-016-2577-6
|
| 20 |
Yang Yang, Yaling Li, Ruiqun Qi, Lan Zhang. Development and Validation of a Combined Glycolysis and Immune Prognostic Model for Melanoma. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.711145
|
| 21 |
Joseph M. McGraw, Deborah A. Witherden. γδ T cell costimulatory ligands in antitumor immunity. Exploration of Immunology 2022; : 79 doi: 10.37349/ei.2022.00038
|
| 22 |
Roshanak Derakhshandeh, Sonia Sanadhya, Kyu Lee Han, Haiyan Chen, Olga Goloubeva, Tonya J. Webb, Rania H. Younis. Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype. Oncotarget 2018; 9(13): 11126 doi: 10.18632/oncotarget.24277
|
| 23 |
Chen Zhang, Hongjiang Qiao, Weinan Guo, Yuan Liu, Luting Yang, Yufeng Liu, Boquan Jin, Meng Fu, Gang Wang, Wei Li. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis. Cancer Letters 2019; 455: 1 doi: 10.1016/j.canlet.2019.04.013
|